Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

Chao Jian, Mei Juan Tu, Pui Yan Ho, Zhijian Duan, Qianyu Zhang, Jing Xin Qiu, Ralph W deVere White, Theodore Wun, Primo N Lara, Kit Lam, Ai Xi Yu, Aiming Yu

Research output: Contribution to journalArticle

10 Scopus citations


Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target. This study was aimed at assessing the hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and protein molecules to achieve "saturation attack" against metastasis. Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR- 34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination. Consequently, triple-drug treatment showed a strong synergism in suppressing 143B cell proliferation and the greatest effects in reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous metastases mouse models, while none showed significant toxicity. In addition, tripledrug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.

Original languageEnglish (US)
Pages (from-to)30742-30755
Number of pages14
Issue number19
StatePublished - 2017



  • Doxorubicin
  • Metastasis
  • MiR-34a
  • Pathology Section
  • Sorafenib
  • Therapy

ASJC Scopus subject areas

  • Oncology

Cite this